29 August 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of pembrolizumab in the NHS in England.

For the time being, pembrolizumab is not recommended for the adjuvant treatment of adults with non-small-cell lung cancer that is at high risk of recurrence after complete resection and platinum-based chemotherapy.

Read NICE draft guidance consultation